3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
1
Endocrine
1
Conditions
Pathologic Complete Response
1
Colorectal Neoplasms
1
Carcinoma, Neuroendocrine
1
Interventions
pembrolizumab
1254
Specimen Handling
869
Carboplatin
818
Magnetic Resonance Spectroscopy
804
Cyclophosphamide
795
Cisplatin
716
Nivolumab
648
Paclitaxel
623
Radiotherapy
567
Gemcitabine
565
Biopsy
529
Bevacizumab
468
Dexamethasone
434
fludarabine
404
Docetaxel
373
venetoclax
366
Oxaliplatin
362
Capecitabine
353
Fluorouracil
352
atezolizumab
341
Rituximab
327
durvalumab
326
Doxorubicin
313
Radiosurgery
306
Pemetrexed
303
Drug Therapy
295
Standard of Care
292
Ipilimumab
290
Etoposide
280
Radiation
278
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
FOLFOXIRI protocol
×
1 year
×
Clear all
NCT02350530
2026-05-22
FORBES
Sun Yat-sen University
Phase 2
Completed
138 enrolled
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled
NCT04325425
2025-09-30
FOLFIRINEC
Centre Hospitalier Universitaire Dijon
Phase 2
Recruiting
218 enrolled